Macro Group Pharmaceutical S.a.e. · EGX:MCRO
Macro Group Pharmaceutical S.a.e — FY2022 Earnings Presentation
23 slides from Macro Group Pharmaceutical S.a.e's earnings presentation, Apr 1, 2026
Slide 1: Investor Relations Presentation FY 2022
Investor Relations Presentation FY 2022
Slide 2: Agenda
Agenda 1 Company Overview 2 FY22 Financial & Operational Performance 3 Appendix
Slide 3: Company Overview
Company Overview
Slide 4: 20 years' presence in Egypt's fast-growing cosmeceutical space
20 years’ presence in Egypt’s fast-growing cosmeceutical space Key Corporate Milestones Inception Development Phase Institutionalization Value Creation Next Growth Phase Founded by Dr. El Gradual shift towards Launch of 3 new Launch of 2 new Nayeb and partner offering therapeutic areas therapeutic a
Slide 5: Bridging the Gap Between Cosmetics and Pharmaceuticals
Bridging the Gap Between Cosmetics and Pharmaceuticals Cosmeceuticals, cosmetic products with active ingredients, bridging the gap between over-the-counter cosmetics and prescription-based drugs COSMETICS COSMECEUTICALS PHARMACEUTICALS Cosmetics are products that are rubbed, poured, sprinkled Offeri
Slide 6: Leading player in Egypt's cosmeceuticals industry
Leading player in Egypt’s cosmeceuticals industry The leading and one of the Attractive portfolio of 149 fastest-growing cosmeceutical SKUs across a variety of Established in 2005, Macro Group is Most of its products manufactured in-house companies in Egypt therapeutic areas principally engaged in t
Slide 7: With strong barriers to entry
With strong barriers to entry Established distribution Extensive marketing budget & Pioneers in the Cosmeceuticals space network & capabilities continuous innovation Facility built in 2010 with ample room for growth without Defensive prescription-based sales model Marketing budget allows for standal
Slide 8: Operating across a variety of high-growth therapeutic areas
Operating across a variety of high-growth therapeutic areas Macro Group boasts a highly attractive portfolio of market leading brands across its different subsegments FY21(1) Market Positioning Therapeutic Areas Female Intimate Skin Care Hair Care Anti-Scar Oral Care Antiseptics Analgesics Nutraceut
Slide 9: Supported by extensive & robust sales capabilities
Supported by extensive & robust sales capabilities… MACRO Advantage An Innovative Market Research and Concept Development Approach, Closing the Customers, Doctors and Pharmacies Feedback Loop Doctors Recommend Express Need Products Highly-incentivized salesforce Provide Feedback Customers Sales Team
Slide 10: …and an efficient distribution platform with wide coverage
…and an efficient distribution platform with wide coverage The promotion team is complemented by its recently expanded and highly capable and incentivized distribution team, which provides market penetration and national-level coverage across all channels Distribution Team Coverage Distribution Chan
Slide 11: Well-Invested Production Facility with Capacity for Growth
Well-Invested Production Facility with Capacity for Growth Macro produces most of its portfolio at its modern, well-invested manufacturing facility with top-of-the line equipment and ample capacity for significant growth Key Machinery 3rd Industrial Zone in Liquids Creams Soap Badr City, Cairo Semi-
Slide 12: Solid track record in launching new products
Solid track record in launching new products Macro Group has introduced 59 new products between 2020 and 2022, which cumulatively generated revenues of EGP 58 million by 2022, up by c.15-fold from 2020 and representing an 8% contribution to total revenues for the year 59 products EGP 58 mn 1 Total p
Slide 13: Financial & Operational Performance
FY22 | Financial & Operational Performance
Slide 14: FY22 Year in Review
FY22 | Year in Review Macro has recorded a robust growth in both its financial and operational performance, with revenues up by 23% YoY in FY22, driven by increasing average pricing, which trickled down to bottom-line expansion of 18% YoY New Launches Premium Brands Exports Inorganic Expansion A tot
Slide 15: Top-Selling Brands in FY22
Top-Selling Brands in FY22 Female Intimate Topical Muscle Oral Care Anti-Scar Skin Care Skin Care Skin Care Skin Care Hair Care Skin Care Care Relaxant 14 SKUs 7 SKUs 4 SKUs 2 SKUs 5 SKUs 5 SKUs 3 SKUs 2 SKUs 13 SKUs 5 SKUs 10% 9% 8% 8% 6% 5% 5% 3% 3% 3% 73.4 65.1 60.0 58.2 42.8 37.8 35.3 24.3 22.2
Slide 16: FY22 Sales Breakdown & Analysis
FY22 | Sales Breakdown & Analysis Revenue Analysis by Therapeutic Area Volumes & Revenues by Therapeutic Area | FY22 ◼ FY21 ◼ FY22 ⚫ YoY Growth ◼ Skin Care Volumes Revenues 38.2% -4.8% 22.3% 24.5% 15.7% 34.0% 6.6% 14.5% 0.4% 0.5% ◼ Hair Care 305.0 6% ◼ Female Care 6% 3% 5% 220.7 3% 10% ◼ Oral Care 1
Slide 17: FY22 Income Statement Highlights
FY22 | Income Statement Highlights FY22 Highlights Revenues(1) Revenue by Channel | FY22 FY21 Volume Sold • Macro’s total revenues came in at EGP 729.6 million in FY22, up by (EGP mn) (EGP mn / % contribution) (mn units) 23% YoY largely driven by an increase in average pricing of 26% YoY to reach EG
Slide 18: FY22 Balance Sheet Highlights
FY22 | Balance Sheet Highlights Net Working Capital Total Debt Short-Term Debt NetDebt/EBITDA Net Debt/EBITDA CAPEX (EGP mn / % change) (EGP mn / % change) (EGP mn / % change) (x) (% change) (EGP mn / % Change) ADIB AUBE 1.0% 0.7% 441.1 160.5 58.4 132.6 0.1x 21% 365.3 119% 57.0 5.8 9% 127% 119% 5.3
Slide 19: FY22 Working Capital Analysis
FY22 | Working Capital Analysis Cash Conversion Cycle | CCC Cash Conversion Cycle (CCC) 89 days 185 129 17 days 146 40 days • MACRO’s CCC recorded 185 days in FY22, reflecting an increase of 40 days during the year, primarily driven by a 101-day increase in inventory DIO, 40 which was partially
Slide 20: Appendix
OY QO Appendix
Slide 21: FY22 Consolidated Income Statement
FY22 | Consolidated Income Statement FY-2021 FY-2022 % CHG Consolidated Income Statement | EGP Actual Actual Y-o-Y Sales Revenue 594,259,209 729,611,988 22.8% COGS (120,388,509) (167,969,291) 39.5% Gross Profit 473,870,700 561,642,697 18.5% Gross profit margin 79.7% 77.0% -2.8 pps G&A Expenses (70,8
Slide 22: FY22 Consolidated Balance Sheet
FY22 | Consolidated Balance Sheet % CHG Consolidated Balance Sheet | EGP 31-Dec-21 31-Dec-22 Y-o-Y Inventories 65,616,582 138,732,545 111.4% Trade and notes receivables 337,895,974 368,327,924 9.0% Prepayments & other debit balances 12,230,850 38,694,998 216.4% Due from Related Parties 0 0 n/a Cash
Slide 23: FY22 Consolidated Cash Flow Statement
FY22 | Consolidated Cash Flow Statement % CHG % CHG Consolidated Cash Flow Statement | EGP FY21 FY22 (Continued) FY21 FY22 Y-o-Y Y-o-Y Cash flows from operating activities Cash flows from investing activities Profit for the year before income tax 196,462,095 227,354,421 15.7% Payments to purchase of
Macro Group Pharmaceutical S.A.E. — FY2022 Earnings Presentation on 6ix